Madrigal's Rezdiffra will have the NASH market all to itself -- at least for a while.
Cash position2 at €87.2 m as of June 30, 2022Revenues of €0.1 m in H1 2022Inventiva entered into a finance loan and a warrant agreement for up to €50...
Daix (France), Long Island City (New York, United States), July 21, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical...
The Phase IIa Proof-of-Concept study is designed to assess the safety and efficacy of lanifibranor in combination with the SGLT2 inhibitor empagliflozin...
Inventiva successfully raised approximately €14.6 million through a combination of its ATM Program for €9.3 million and new State-backed bank financing for...
Update on Inventiva’s NATiV3 Phase III clinical trial evaluating lanifibranor in patients with NASH and fibrosis (stage F2/F3) non-cirrhotic by Prof. Sven...
Three poster presentations showing the beneficial effects of lanifibranor on markers of cardiometabolic health in patients with non-cirrhotic NASH...
Inventiva has been selected for inclusion in Euronext’s new segment alongside more than 100 high-growth and Tech-driven European companiesInternational...
Daix (France), Long Island City (New York, United States), June 3, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical...
Daix (France), Long Island City (New York, United States), May 23, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage...